PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+5.62%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$143M
AUM Growth
-$9.08M
(-6%)
Cap. Flow
-$8.5M
Cap. Flow
% of AUM
-5.96%
Top 10 Holdings %
Top 10 Hldgs %
33.62%
Holding
128
New
4
Increased
25
Reduced
59
Closed
17
Avg Time Held
2.6
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rockwell Medical
RMTI
|
+$2.34M |
| 2 |
Veritone
VERI
|
+$939K |
| 3 |
QuickLogic
QUIK
|
+$939K |
| 4 |
DarioHealth
DRIO
|
+$540K |
| 5 |
TON Strategy Co
TONX
|
+$487K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CYBE
Cyberoptics Corp
CYBE
|
+$1.23M |
| 2 |
AngioDynamics
ANGO
|
+$1.05M |
| 3 |
Vericel Corp
VCEL
|
+$992K |
| 4 |
NVTA
Invitae Corporation
NVTA
|
+$939K |
| 5 |
QTNA
Quantenna Communications, Inc. Common Stock
QTNA
|
+$754K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.36% |
| 2 | Technology | 17% |
| 3 | Industrials | 6.45% |
| 4 | Communication Services | 5.82% |
| 5 | Consumer Staples | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Vericel Corp
VCEL
$2.06B
| $8.06M | 5.65% |
426,950
-58,200
| -12% | -$992K |
2014 Q3
19 quarters
|
|
2
Axogen
AXGN
$2.06B
| $6.73M | 4.71% |
339,775
-9,350
| -3% | -$200K |
2013 Q3
23 quarters
|
|
3
NeoGenomics
NEO
$2.17B
| $6.14M | 4.3% |
279,700
+15,050
| +6% | +$330K |
2013 Q2
24 quarters
|
|
4
Veracyte
VCYT
$3.5B
| $4.83M | 3.38% |
169,380
-28,060
| -14% | -$701K |
2018 Q1
5 quarters
|
|
5
CareDx
CDNA
$3.35B
| $4.56M | 3.19% |
126,750
-5,150
| -4% | -$165K |
2017 Q3
7 quarters
|
|
6
Magnite
MGNI
$3.42B
| $3.67M | 2.57% |
577,100
-53,250
| -8% | -$327K |
2018 Q2
4 quarters
|
|
7
Standard BioTools
LAB
$248M
| $3.67M | 2.57% |
297,800
-33,350
| -10% | -$425K |
2017 Q4
6 quarters
|
|
8
Natera
NTRA
$56.9B
| $3.49M | 2.44% |
126,500
-3,400
| -3% | -$75K |
2018 Q2
4 quarters
|
|
9
OptimizeRx
OPRX
$156M
| $3.45M | 2.41% |
212,793
-1,168
| -0.5% | -$15.8K |
2018 Q2
4 quarters
|
|
|
TEUM
10
DELISTED
Pareteum Corporation
TEUM
| $3.42M | 2.39% |
1,309,931
-35,476
| -3% | -$140K |
2017 Q1
9 quarters
|
|
|
CSII
11
DELISTED
Cardiovascular Systems, Inc.
CSII
| $3.28M | 2.3% |
76,400
-3,250
| -4% | -$126K |
2013 Q2
24 quarters
|
|
12
Idexx Laboratories
IDXX
$41.7B
| $3.13M | 2.19% |
11,350
-2,000
| -15% | -$493K |
2013 Q3
23 quarters
|
|
|
13
Veritone
VERI
$53.8M
| $3.1M | 2.17% |
371,450
+126,450
| +52% | +$939K |
2019 Q1
1 quarter
|
|
14
Abbott
ABT
$178B
| $3M | 2.1% |
35,661
-3,493
| -9% | -$275K |
2014 Q1
21 quarters
|
|
15
CryoPort
CYRX
$843M
| $3M | 2.1% |
163,520
-10,130
| -6% | -$161K |
2016 Q1
13 quarters
|
|
|
16
Rockwell Medical
RMTI
$30.9M
| $2.87M | 2.01% |
8,662
+4,614
| +114% | +$2.34M |
2013 Q2
24 quarters
|
|
17
Digital Turbine
APPS
$1.16B
| $2.85M | 1.99% |
569,300
-85,595
| -13% | -$344K |
2015 Q1
17 quarters
|
|
18
Pfizer
PFE
$166B
| $2.51M | 1.76% |
61,069
-1,590
| -3% | -$63.1K |
2013 Q2
24 quarters
|
|
19
ANI Pharmaceuticals
ANIP
$1.61B
| $2.45M | 1.72% |
29,800
-2,750
| -8% | -$196K |
2017 Q1
9 quarters
|
|
20
Microsoft
MSFT
$3.96T
| $2.36M | 1.65% |
17,635
-75
| -0.4% | -$9.52K |
2014 Q1
21 quarters
|
|
21
Eli Lilly
LLY
$1.08T
| $2.24M | 1.57% |
20,235
-475
| -2% | -$55.9K |
2013 Q2
24 quarters
|
|
22
DELISTED
Cantaloupe
CTLP
| $2.16M | 1.51% |
290,360
+2,425
| +0.8% | +$15K |
2014 Q1
21 quarters
|
|
23
Sensus Healthcare
SRTS
$47.1M
| $2.04M | 1.43% |
368,536
-14,500
| -4% | -$85K |
2018 Q2
4 quarters
|
|
24
AtriCure
ATRC
$2.91B
| $1.81M | 1.27% |
60,750
-5,000
| -8% | -$146K |
2013 Q2
24 quarters
|
|
25
Tactile Systems Technology
TCMD
$508M
| $1.77M | 1.24% |
31,024
-1,750
| -5% | -$91.2K |
2017 Q4
6 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Perkins Capital Management held 128 positions worth $143M, down 6% from $152M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Perkins Capital Management withdrew a net $8.5M in Q2 2019, closing 17 positions and reducing 59 holdings. Its most notable exit was Cyberoptics Corp, an estimated $1.23M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 64% a quarter earlier, followed by Technology and Industrials.
Against the trend, Perkins Capital Management opened a new position in QuickLogic worth $748K.
- Perkins Capital Management's largest Q2 2019 buy was QuickLogic: 92,857 shares worth $748K.
- Perkins Capital Management added most to Rockwell Medical in Q2 2019, an estimated $2.34M increase.
- Perkins Capital Management's biggest Q2 2019 reduction was Vericel Corp, cutting an estimated $992K.
- Perkins Capital Management fully exited Cyberoptics Corp in Q2 2019, selling an estimated $1.23M.
- Perkins Capital Management's ten largest holdings make up 34% of its $143M portfolio in Q2 2019.
- Perkins Capital Management opened 4 new positions and closed 17 in Q2 2019.
- Perkins Capital Management's portfolio value fell 6% quarter-over-quarter to $143M.
Based on Perkins Capital Management's 13F filing for Q2 2019, filed 9 Aug 2019.